These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

661 related items for PubMed ID: 15830348

  • 1. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy.
    Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J.
    Cancer; 2005 May 15; 103(10):2082-90. PubMed ID: 15830348
    [Abstract] [Full Text] [Related]

  • 2. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
    Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, Patil SR, Davey FR, Berg DT, Schiffer CA, Arthur DC, Mayer RJ.
    Cancer Res; 1998 Sep 15; 58(18):4173-9. PubMed ID: 9751631
    [Abstract] [Full Text] [Related]

  • 3. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
    Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X.
    Ann Hematol; 2003 Nov 15; 82(11):684-90. PubMed ID: 12928754
    [Abstract] [Full Text] [Related]

  • 4. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.
    Ann Hematol; 2004 Aug 15; 83(8):498-503. PubMed ID: 15156346
    [Abstract] [Full Text] [Related]

  • 5. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study.
    Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lübbert M.
    Ann Hematol; 2003 Jul 15; 82(7):381-9. PubMed ID: 12756497
    [Abstract] [Full Text] [Related]

  • 6. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children's Cancer Group Study 2891.
    Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO, Children's Cancer Group Study 2891.
    J Clin Oncol; 2003 Sep 15; 21(18):3415-22. PubMed ID: 12885836
    [Abstract] [Full Text] [Related]

  • 7. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M, Tokyo Children's Cancer Study Group.
    Pediatr Blood Cancer; 2007 Aug 15; 49(2):127-32. PubMed ID: 16807916
    [Abstract] [Full Text] [Related]

  • 8. [Effectiveness analysis of HA based triple-drug regimen as induction chemotherapy in the treatment of acute myeloid leukemia and its relationship with karyotype].
    Mi YC, Xue YP, Yu WJ, Liu SH, Zhao YZ, Meng QX, Bian SG, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Dec 15; 26(12):705-9. PubMed ID: 16620570
    [Abstract] [Full Text] [Related]

  • 9. [Acute myeloid leukemia in those over 70 years of age. Experience using low-dose ara-C treatment].
    Rodríguez JN, Fernández-Jurado A, Martino ML, Diéguez JC, Moreno MV, Quesada JA, Polo B, Cañavate M, Amian A, Prados D.
    Sangre (Barc); 1998 Feb 15; 43(1):35-9. PubMed ID: 9580427
    [Abstract] [Full Text] [Related]

  • 10. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J, Mi Y, Fu M, Yu W, Wang Y, Lin D, Bian S, Wang J.
    Am J Hematol; 2009 Jul 15; 84(7):422-7. PubMed ID: 19484734
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes.
    Knipp S, Hildebrand B, Kündgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U.
    Cancer; 2007 Jul 15; 110(2):345-52. PubMed ID: 17559141
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
    Niparuck P, Chuncharunee S, Ungkanont A, Udomtrupayakul U, Aungchaisuksiri P, Rerkamnuatchoke B, Jootar S, Atichartakarn V.
    J Med Assoc Thai; 2009 Sep 15; 92(9):1143-9. PubMed ID: 19772172
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors.
    Stasi R, Venditti A, Del Poeta G, Aronica G, Dentamaro T, Cecconi M, Stipa E, Scimò MT, Masi M, Amadori S.
    Cancer; 1996 Jun 15; 77(12):2476-88. PubMed ID: 8640696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.